iVIEW-1501

Description: PVP-I/Budesonide Nasal Irrigation and Nasal Spray

Treatment: Chronic sinusitis

Progress: Finished 5 patients study in US

Budesonide and PVP-I Combination
Chronic rhinosinusitis is a common clinical problem with significant morbidity and often-refractory symptoms that accounts for approximately 26.7 million office and emergency visits per year in the US.
Annual global treatment of allergic rhinitis drug sales reached $ 6 billion (1); while China’s 2010 total nasal drug costs 650 million to 780 million RMB (2)
IP Protection: WO 2012177251“Pharmaceutical Compositions Comprising Iodine and Steroid and Uses Thereof for Sinus Diseases”
Development Status: Accomplished formulation and stability studies, in-vitro biofilm studies, and 9-patients human proof-of-concept trials in Connecticut Sinus Institute

Pennsylvania Biotechnology Center at Bucks County
3805 Old Easton Road
Doylestown PA 18902 USA
Copyright © 2021 iVIEW Therapeutics, Inc. All rights reserved.